GENE THERAPY DURING EX-VIVO LUNG PERFUSION FOR TREATMENT OF PRIMARY GRAFT DYSFUNCTION AFTER LUNG TRANSPLANTATION KU Leuven
Lung transplantation (LTx) is the ultimate therapy for patients with
end-stage lung disease. However, survival is poor (56% at 5 years)
compared to other solid organ transplants. Primary Graft Dysfunction
(PGD) is an important risk factor for poor survival. Severe PGD
occurs in 30% of patients after LTx and presents as lung edema,
impaired gas exchange and decreased compliance. Treatment
options for PGD however ...